|
|
Vaccine Detail
|
MUC1-MPA11P-Pulsed DC Vaccine |
| Vaccine Information |
- Vaccine Name: MUC1-MPA11P-Pulsed DC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Dendritic cell vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: 30-mer MUC1 (APDTRPAPGSTAPPAHGVTSAPDTRPAPGS) (Kobukai et al., 2011)
- Immunization Route: subcutaneous injection
- Description: A dendritic cell vaccine in which bone marrow-derived immature DCs are pulsed overnight with 40 µM MUC1-MPA11P (30-mer MUC1 peptide conjugated to myristoylated polyarginine 11-mer delivery module) and administered via subcutaneous footpad injection (1×10⁶ DCs/dose) in two doses 10 days apart to MUC1 transgenic (MUC1.Tg) C57BL/6 mice bearing C57MG-MUC1 mammary tumors. MUC1.Tg mice are immunologically tolerant to MUC1, and the vaccine successfully broke this self-tolerance, inducing meaningful antitumor immune responses. Superior intracellular antigen concentration via MPA11P was confirmed by confocal immunocytochemistry, with both MUC1 and MUC1-MPA11P showing endosomal colocalization. In vitro, both MUC1-MPA11P- and MUC1-pulsed DCs induced robust CD8⁺ T-cell proliferation with no CD4⁺ response in either group. In vivo, MUC1-MPA11P-pulsed DC-treated mice showed significantly greater tumor suppression over 30 days compared to MUC1-pulsed DCs, DCs alone, and untreated controls (p<0.05), measured by high-resolution ultrasound volumetry. Serum TNF-α and IFN-γ levels were significantly elevated at day 30 (p=0.0001). TUNEL assay revealed 1.72-fold higher tumor apoptosis versus MUC1-pulsed DC group. DC migration from footpad to popliteal lymph nodes was confirmed by MRI at 24 hours post-injection (Kobukai et al., 2011).
|
| Host Response |
|
|
| References |
Kobukai et al., 2011: Kobukai S, Kremers GJ, Cobb JG, Baheza R, Xie J, Kuley A, Zhu M, Pham W. Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen. Translational oncology. 2011; 4(1); 1-8. [PubMed: 21286372].
|
|
